In an elderly patient with severe agitation who is also receiving valproic acid (Depakote), does Abilify (aripiprazole) cause hyponatremia?

Does Abilify Cause Hyponatremia?

Yes, Abilify (aripiprazole) can cause hyponatremia, though it appears to carry a lower risk compared to other antipsychotics like olanzapine. However, in your elderly patient already receiving valproic acid (Depakote), the combination significantly increases hyponatremia risk and requires careful monitoring.

The Evidence on Aripiprazole and Hyponatremia

Direct Risk from Aripiprazole

While the FDA label for Abilify does not list hyponatremia as a prominent adverse effect 1, multiple case reports document aripiprazole-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH):

• Rechallenge cases confirm causality: A patient developed hyponatremia twice upon rechallenge with aripiprazole, establishing a clear causal relationship 2
• Rapid onset documented: Hyponatremia can occur as quickly as 3 days after starting aripiprazole 3
• Severe presentations reported: A 65-year-old patient developed severe hyponatremia (serum sodium 108 mEq/L) after aripiprazole dose increase from 10 to 20 mg, with recurrence upon inadvertent rechallenge 4

Comparative Risk Profile

The most recent high-quality evidence shows aripiprazole has a favorable safety profile for hyponatremia compared to other antipsychotics. A 2026 retrospective cohort study of 55,394 patients found aripiprazole was associated with significantly lower risk of hyponatremia than olanzapine (adjusted hazard ratio 0.52; 95% CI: 0.35-0.76) 5. This makes aripiprazole one of the safer choices among second-generation antipsychotics for hyponatremia risk.

Critical Concern: Valproic Acid Interaction

Your patient's concurrent valproic acid therapy substantially elevates hyponatremia risk. Valproic acid is well-established as causing hyponatremia 6, and the combination of valproate with dopaminergic drugs has been documented to cause refractory hyponatremia 7. This creates a dangerous prescribing cascade where:

1. Valproate independently causes hyponatremia
2. Adding aripiprazole compounds this risk
3. The combination can produce treatment-resistant hyponatremia requiring deprescribing as the only effective therapy 7

Clinical Approach for Your Patient

Before Starting Aripiprazole:

• Obtain baseline serum sodium, serum osmolality, and renal function
• Document current sodium level given valproate exposure
• Assess for existing signs of hyponatremia (confusion, lethargy, nausea)

Monitoring Strategy:

• Check serum sodium at 3 days, 1 week, and 2 weeks after initiation (based on documented rapid onset 3)
• Continue monthly monitoring for first 3 months
• Watch for symptoms: confusion, headache, nausea, dizziness, lethargy

Red Flags Requiring Immediate Action:

• Serum sodium <125 mEq/L
• Any neurological symptoms (altered mental status, seizures)
• Rapid decline in sodium (>5 mEq/L in 24 hours)

If Hyponatremia Develops:

1. Stop aripiprazole immediately - rechallenge data shows recurrence is likely 2, 4
2. Consider deprescribing valproate if clinically feasible 7
3. Implement fluid restriction
4. Do NOT rechallenge with aripiprazole if severe hyponatremia occurred

Context: Elderly Patients with Agitation

The 2025 JAGS guidelines on geriatric agitation did not specifically study aripiprazole but found that oral antipsychotics have better safety profiles than parenteral formulations 8. Quetiapine showed the lowest adverse event rate (OR 0.27) among studied medications 8. However, these studies focused on respiratory depression, dysrhythmia, hypotension, and delirium - not specifically hyponatremia.

Important caveat: The FDA warns that elderly patients with dementia-related psychosis have increased mortality risk with antipsychotics, and Abilify is not approved for this indication 1. Your patient's agitation etiology matters significantly for medication selection.

Bottom Line

Aripiprazole can cause hyponatremia but carries lower risk than alternatives like olanzapine 5. However, the combination with valproic acid in an elderly patient creates substantial risk for refractory hyponatremia 7. If you proceed with aripiprazole, implement aggressive sodium monitoring starting at 3 days post-initiation, and maintain a low threshold for discontinuation if any sodium decline occurs. Consider whether alternative agitation management (quetiapine if antipsychotic needed, or addressing underlying valproate-related issues) might be safer for this high-risk patient.